Date: 2011-12-19
Type of information: Grant
Company: Argen-X (The Netherlands-Belgium)
Investors: Flemish agency for Innovation by Science and Technology (IWT) (Belgium)
Amount: €1.3 million
Funding type: grant
Planned used: arGEN-X has received a grant of €1.3 million to further advance its discovery platform for addressing challenging disease targets. Its SIMPLE Antibody™platform enables the production of multiple novel and diverse leads against complex soluble, cell surface and highly conserved targets. arGEN-X has used this platform to generate its own pipeline of therapeutic antibodies. The Company has five therapeutic programs under development for the treatment of autoimmune disorders, inflammation and oncology, with two now in formal preclinical development. Its most advanced program, ARGX-110, addresses a clinically validated cell surface receptor implicated in autoimmunity and cancer and has been shown in preclinical models to modulate target function with unrivalled potency. arGEN-X expects to file an IND application for ARGX-110 in early 2013.
Others: The grant was awarded by the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT), and is the third award the Company has received from the institute, totalling €4.1 million to date.
Therapeutic area: Cancer - Oncology - Autoimmune diseases
